Proximal Myotonic Myopathy (DM2/PROMM) Supportive Care Protocol

Proximal Myotonic Myopathy (PROMM), also called Myotonic Dystrophy Type 2 (DM2), is a genetic muscle disorder caused by a mutation in the CNBP/ZNF9 gene. Unlike the more common DM1 (which affects distal muscles first), DM2 primarily affects proximal muscles (hips, thighs, shoulders). Symptoms include muscle weakness, myotonia (difficulty relaxing muscles), muscle pain, fatigue, cataracts, and sometimes heart and endocrine problems. Symptoms typically begin in adulthood and are generally milder than DM1.

CRITICAL: DM2/PROMM requires management by a neuromuscular specialist. There is no cure, but management focuses on: monitoring for cardiac issues (EKG, may need pacemaker), screening for cataracts, managing diabetes if it develops, treating pain and fatigue, physical therapy to maintain function, and avoiding certain anesthetics (can cause complications). Annual cardiac screening is essential as arrhythmias and conduction defects can occur. These supplements may support muscle health but are NOT treatments for the underlying genetic condition.

* Vitamin D supports muscle function, and deficiency is common in neuromuscular disorders. Maintaining adequate levels may help preserve strength.

* Creatine has been studied in muscular dystrophies with some evidence of modest benefit for muscle strength and function.

* Coenzyme Q10 supports mitochondrial function in muscle and may help with the fatigue that is common in DM2.

* L-Carnitine supports muscle energy metabolism.

* Omega-3 Fatty Acids have anti-inflammatory effects.

* Magnesium supports muscle function and may help with muscle pain and cramps.

* Taurine is abundant in muscle and has been specifically studied for myotonic disorders.

* Vitamin E provides antioxidant protection for muscle membranes.

Expected timeline: Supplements provide supportive benefits over months of use. DM2 typically progresses slowly - maintenance of muscle function through physical therapy and supportive care is the goal.

Clinical Perspective

Proximal Myotonic Myopathy/Myotonic Dystrophy Type 2 (DM2): autosomal dominant repeat expansion disorder caused by CCTG repeat expansion in CNBP gene (chromosome 3). Prevalence: 1:8000-20000. Phenotype: proximal weakness (hip flexors, neck flexors), myotonia (often mild, grip/percussion myotonia), muscle pain (common), fatigue, cataracts, cardiac conduction defects, insulin resistance, frontal balding. Onset: typically 30-60 years; milder and later than DM1.

CRITICAL: Multidisciplinary management: neuromuscular specialist, cardiology (annual EKG minimum; Holter or EP study if symptomatic; pacemaker if conduction defects), ophthalmology (cataracts - may need early surgery), endocrinology (diabetes screening), anesthesiology consultation before surgery (avoid succinylcholine, minimize respiratory depressants). Physical therapy for function maintenance. Pain management often challenging. No disease-modifying treatment available. Supplements are SUPPORTIVE - no cure for genetic disorder.

* Vitamin D (B-grade): Muscle function; common deficiency. Systematic review: neuromuscular disorders (PMID: 28472918). 2000-4000 IU daily.

* Creatine (B-grade): Muscle energy; modest benefit in dystrophies. Cochrane review: muscular dystrophies (PMID: 23897405). 3-5g daily.

* CoQ10 (C-grade): Mitochondrial support; fatigue. Systematic review: neuromuscular disorders (PMID: 25268557). 200-400mg daily.

* L-Carnitine (C-grade): Muscle metabolism. Review: muscle disorders (PMID: 24140491). 1-2g daily.

* Omega-3 (C-grade): Anti-inflammatory. Review: muscle health (PMID: 27453218). 1-2g daily.

* Magnesium (C-grade): Muscle function; cramping. Review: (PMID: 28150472). 300-400mg daily.

* Taurine (C-grade): Abundant in muscle; myotonia. Study: myotonic disorders (PMID: 19015158). 1-3g daily.

* Vitamin E (D-grade): Antioxidant. Review: neuromuscular disorders (PMID: 16936087). 400 IU daily.

Assessment targets: Muscle strength testing (MRC scale), grip strength (dynamometer), timed functional tests (6MWT, stair climb), EKG, HbA1c, CK levels, quality of life measures.

Protocol notes: Cardiac monitoring: essential - conduction defects can be life-threatening; annual EKG minimum; Holter if palpitations; low threshold for EP study. Anesthesia: inform all providers of diagnosis; avoid succinylcholine (severe myotonia); careful with respiratory depressants; malignant hyperthermia-like reactions possible. Cataracts: posterior subcapsular type; may need surgery earlier than usual age. Myotonia treatment: usually mild in DM2; mexiletine if symptomatic; avoid cold (worsens myotonia). Pain: very common in DM2 (more than DM1); NSAIDs, gabapentin, duloxetine; difficult to treat. Fatigue: major symptom; modafinil or methylphenidate sometimes tried; CoQ10, carnitine supportive. Exercise: low-moderate intensity aerobic and strength training beneficial; avoid exhaustion. Insulin resistance: common; lifestyle modification, metformin if needed. Cognitive: generally preserved in DM2 (unlike DM1). Genetics: genetic counseling for family; prenatal testing available. Physical therapy: stretching, strengthening, balance training. Assistive devices: as needed for mobility. DM1 vs DM2: DM2 typically milder, later onset, proximal weakness pattern, more pain, less cognitive involvement, no congenital form.

View All Protocols